Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Company Stock Begins Trading on OTCBB LEXINGTON, Mass., Dec. 28 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC:MCHM.OB) (BULLETIN BOARD: MCHM.OB) , announced today that it has raised $2.5...
Company Continues Trading on Pink Sheets and Seeks to Move to OTC Bulletin Board LEXINGTON, Mass., Nov. 21 /PRNewswire-FirstCall/ -- MacroChem Corporation (NASDAQ:MCHM) today announced that it...
LEXINGTON, Mass., Oct. 24 /PRNewswire-FirstCall/ -- MacroChem Corporation (NASDAQ:MCHM) today announced that the Company received a Nasdaq Staff Determination on October 18, 2005 indicating that...
LEXINGTON, Mass., Sept. 1 /PRNewswire-FirstCall/ -- At the direction of its board of directors, MacroChem Corporation (NASDAQ:MCHM) is discontinuing all research and product development...
MacroChem CEO Reports on Year of Progress and Innovation at Annual Shareholders' Meeting BOSTON, June 14 /PRNewswire-FirstCall/ -- MacroChem Corp. (NASDAQ:MCHM) president and CEO Robert J...
MacroChem Reports Positive Results From Clinical Trial of Opterone(R) Topical Testosterone Cream* 2.5 Grams of Opterone, Applied to Upper Arms and Shoulders, Raised Average Serum Testosterone...
MacroChem Presents EcoNail(TM) Clinical Data at Society for Investigative Dermatology Annual Meeting (1) LEXINGTON, Mass., May 6 /PRNewswire/ -- Thomas Chan, PhD, vice president of R&D and chief...
MacroChem Granted Extension to Regain Compliance With Nasdaq Minimum Bid Price Requirement LEXINGTON, Mass., April 20 /PRNewswire-FirstCall/ -- MacroChem Corporation (NasdaqSC: MCHM), announced...
MacroChem to Present EcoNail(TM) Clinical Data at Society For Investigative Dermatology Meeting Full 18-week data set confirms 6-week safety-tolerability findings previously reported LEXINGTON...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
